本文選題：血管內(nèi)皮生長(zhǎng)因子受體2 + 融合蛋白　； 參考：《浙江大學(xué)》2006年碩士論文

【摘要】：惡性腫瘤的生長(zhǎng)、浸潤(rùn)和轉(zhuǎn)移必須依靠腫瘤新生血管提供足夠的營(yíng)養(yǎng),因此抑制或破壞腫瘤血管生成已成為近年來(lái)腫瘤治療的新方法。血管內(nèi)皮生長(zhǎng)因子(VEGF)與表達(dá)在血管內(nèi)皮細(xì)胞上的相應(yīng)受體VEGFR2結(jié)合所引起的信號(hào)轉(zhuǎn)導(dǎo)是血管生成中的限速步驟,在整個(gè)血管生成中發(fā)揮著關(guān)鍵作用。可溶性血管內(nèi)皮生長(zhǎng)因子受體2(sVEGFR2,在小鼠中被稱(chēng)為sflkl)可競(jìng)爭(zhēng)性地結(jié)合VEGF,從而阻斷VEGF與VEGFR2結(jié)合所引起的信號(hào)轉(zhuǎn)導(dǎo),抑制腫瘤細(xì)胞誘導(dǎo)的血管生成和腫瘤的生長(zhǎng)。IFN-γ是細(xì)胞介導(dǎo)的免疫應(yīng)答中非常重要的效應(yīng)因子,能誘導(dǎo)CTL應(yīng)答及Th1細(xì)胞的分化,并且尚能直接抑制多種腫瘤的生長(zhǎng),同時(shí)它自身也有抑制腫瘤血管生成的作用。因此我們構(gòu)建了pcDNA3.1(+)/sflk1-IFN-γ重組質(zhì)粒,將其在CHO細(xì)胞中高效穩(wěn)定表達(dá),并對(duì)其表達(dá)產(chǎn)物sflk1-IFN-γ融合蛋白的生物學(xué)活性進(jìn)行了研究鑒定。 目的 構(gòu)建小鼠可溶性的血管內(nèi)皮生長(zhǎng)因子受體2(sflkl)與小鼠IFN-γ(mIFN-γ)融合基因的真核表達(dá)質(zhì)粒pcDNA3.1(+)/silk1—IFN-γ;將該重組質(zhì)粒在CHO細(xì)胞中表達(dá),篩選出高效穩(wěn)定表達(dá)sflk1-IFN-γ融合蛋白的CHO細(xì)胞株;并對(duì)該融合蛋白的生物學(xué)活性進(jìn)行鑒定。
[Abstract]:The growth, invasion and metastasis of malignant tumors must rely on tumor neovascularization to provide adequate nutrition, so inhibition or destruction of tumor angiogenesis has become a new method of tumor treatment in recent years. The signal transduction caused by the binding of vascular endothelial growth factor (VEGF) to the corresponding receptor VEGFR2 expressed on vascular endothelial cells is a rate-limiting step in angiogenesis and plays a key role in the whole angiogenesis. Soluble vascular endothelial growth factor receptor 2sVEGFR2, known as sflkl2 in mice, can competitively bind to VEGF, thus blocking the signal transduction caused by the binding of VEGF to VEGFR2. Inhibiting angiogenesis induced by tumor cells and tumor growth. IFN- 緯 is a very important effector factor in cellular mediated immune response, which can induce CTL response and differentiation of Th1 cells, and can directly inhibit the growth of many kinds of tumors. At the same time, it also has the effect of inhibiting tumor angiogenesis. The recombinant plasmid pcDNA3.1 (/ sflk1-IFN- 緯) was constructed and expressed stably in CHO cells, and the biological activity of the fusion protein sflk1-IFN- 緯 was studied. Purpose The eukaryotic expression plasmid pcDNA3.1 (r-silk1-IFN- 緯) of the fusion gene of soluble vascular endothelial growth factor receptor (sflkl2) and mouse IFN- 緯 was constructed, and the recombinant plasmid was expressed in CHO cells to screen the CHO cell line with high and stable expression of sflk1-IFN- 緯 fusion protein. The biological activity of the fusion protein was identified.
【學(xué)位授予單位】：浙江大學(xué)
【學(xué)位級(jí)別】：碩士
【學(xué)位授予年份】：2006
【分類(lèi)號(hào)】：R392

【共引文獻(xiàn)】

相關(guān)期刊論文 前3條

1 李國(guó)平;王連穩(wěn);;肝癌患者外周血單個(gè)核細(xì)胞膜表面Fas配體表達(dá)及意義[J];醫(yī)學(xué)檢驗(yàn)與臨床;2008年04期

2 李國(guó)平;王連穩(wěn);;肝細(xì)胞肝癌患者血清可溶性Fas檢測(cè)及臨床意義[J];中華全科醫(yī)學(xué);2008年10期

3 張立煌;王青青;;惡性腫瘤免疫治療的現(xiàn)狀及展望[J];浙江大學(xué)學(xué)報(bào)(醫(yī)學(xué)版);2010年04期

相關(guān)碩士學(xué)位論文 前2條

1 劉琴;以VEGFR-2為抗原肽的MHC-I類(lèi)分子—抗原肽單鏈三聚體的構(gòu)建[D];浙江大學(xué);2007年

2 孫翠蓮;sflk1-IFN-γ融合蛋白的分離與純化[D];浙江大學(xué);2007年

，

本文編號(hào)：1922811